microRNAs Tool for Stratifying Stage II Colon Cancer

Launched by FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Dec 17, 2015

Keywords

ClinConnect Summary

This clinical trial is looking at a special tool that uses microRNAs to help doctors determine which patients with stage II colon cancer might benefit from chemotherapy after surgery. The goal is to better predict who will respond positively to treatment, helping to personalize care for patients. The study is currently recruiting participants, and it welcomes individuals of all genders between the ages of 18 and 80, who have been diagnosed with stage II colon cancer and have a good overall health status.

To join the study, participants need to provide informed consent and must not have received any cancer treatment before their surgery. They should have undergone a complete removal of the cancer with clear margins, meaning no cancer cells are left at the edges of the removed tissue. However, individuals with serious health problems, pregnant or breastfeeding women, or those who cannot follow the study's rules are not eligible. Those who participate can expect to contribute to important research that aims to improve treatment decisions for future colon cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The informed consent has been obtained from the patient.
• • With confirmed diagnosis of stage II colon cancer.
• • With moderate/good ECOG health rating (PS): 0-1 score.
• • The patient receive no anti-cancer treatment before primary surgery.
• • The patient receive radical operation for colon cancer with negative margin.
• Exclusion Criteria:
• • With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.
• • With bad compliance or contraindication to enrollment.
• • Pregnant woman or lactating woman.
• • With contraindication to receive adjuvant chemotherapy.